Resilience
Conditions
Brief summary
Remote 5 minute sessions of heart rate variability (HRV) biofeedback will be employed by participants for 5 weeks. Subjects will be followed for a total of 17 weeks. Surveys assessing psychological well being will be completed during the study period. Wearable devices will be worn to monitor HRV response during the study period.
Interventions
BEHAVIORALHRV Biofeedback
5 minute daily sessions of HRV biofeedback
Sponsors
Icahn School of Medicine at Mount Sinai
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants were recruited from The Mount Sinai Hospital, Morningside Hospital, Mount Sinai West, Mount Sinai Beth Israel, Mount Sinai Queens, New York Eye and Ear Infirmary, and Mount Sinai Brooklyn. * Eligible participants were 18 years of age or greater. * Had an iPhone series 5 or greater. * Had or were willing to wear an Apple Watch 4 or greater. * Potential participants were excluded if they had an underlying chronic disease or used a medication that is known to impact autonomic nervous system function.
Exclusion criteria
* Underlying chronic diseases including but not limited to: * rheumatoid arthritis * systemic lupus erythematosus * inflammatory bowel disease * Use of medications that impact heart rate variability including but not limited to: * beta-blockers (ie. atenolol, carvedilol, metoprolol, Coreg, Tenormin, Normodyne, Trandate) * digoxin * calcium channel blockers (ie. Norvasc, amlodipine, Cardene, nicardipine, Procardia, nifedipine, Cardizem, diltiazem) * regularly used benzodiazepines
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart Rate Variability | Up to Week 7 | Heart rate variability measured in milliseconds (ms) at 7 weeks compared to baseline. Higher rates indicate increased parasympathetic nervous system activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Connor-Davidson Resilience Scale (CD-RISC | Up to Week 17 | Resilience: the Connor-Davidson Resilience scale (CD-RISC) quantifies stress coping ability. The CD-RISC is a 25-item self-administered scale. Scoring of the full 25 item scale is based on summing the total of each item, which is scored from 0-4. The full range is therefore from 0 to 100, with higher scores reflecting greater resilience. |
Countries
United States
Outcome results
None listed